[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-biopsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-biopsy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100651987","25-lidocaine25-prilocaine-cream-for-iud-insertion-and-endometrial-biopsy-100651987",false,"NCT07768059","2.5% Lidocaine\u002F2.5% Prilocaine Cream for IUD Insertion and Endometrial Biopsy","A Double-blind Placebo-controlled Randomized Controlled Trial (RCT) of Self-application of Lidocaine 2.5%\u002FPrilocaine 2.5% Cream for Intrauterine Device (IUD) Insertion and Endometrial Biopsy","Inclusion Criteria:\n\n* Any participant ≥18 years presenting for an IUD insertion or endometrial biopsy\n* English speaking participants only\n\nExclusion Criteria:\n\n* Use of pain medication that is not an NSAID or acetaminophen (e.g. opioids, benzodiazepines) within past 24 hours\n* Misoprostol administration within 24 hours\n* Confirmed pregnancy\n* Any diagnosed chronic pain syndromes (e.g. fibromyalgia, vaginismus)\n* Allergy to lidocaine, prilocaine or any other \"-caine\" type anesthetics or any of the non-medicinal ingredients found in the product\n* Patients with congenital or idiopathic methemoglobinemia\n* Patients with glucose-6-phosphate dehydrogenase deficiency\n* Severe kidney or liver disease\n* Previous history of local anesthetic systemic toxicity (LAST)\n* Baseline vital signs of systolic blood pressure \\\u003C100, diastolic blood pressure \\\u003C60 and\u002For pulse \\\u003C60.\n* Previous unsuccessful office attempt of IUD insertion or endometrial biopsy by the same practitioner (note of clarification: previous unsuccessful IUD insertion or biopsy attempt by a different practitioner will still be eligible)\n* Active atopic dermatitis or skin involving vulva, vagina and\u002For cervix.",true,"FEMALE","18 Years",{"count":20,"type":21},174,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study is to determine if 5g of self-administered topical 2.5% lidocaine\u002F2.5% prilocaine cream, reduces pain during IUD insertion and\u002For endometrial biopsy. The proposed study is a double-blind, placebo-controlled RCT. Each participant will be randomly assigned to one of two arms: 1) Intervention (5g of 2.5% lidocaine\u002F2.5% prilocaine cream in a pre-filled vaginal applicator). 2) Placebo (5g of VersaPro cream in a pre-filled vaginal applicator). Participants will be asked to self-administer the pre-filled vaginal applicator at least 10-15 minutes prior to the procedure. The patient will be asked to rate their pain throughout various steps of the procedure and complete a post-procedure survey afterwards. The primary outcome is global pain score, which will be patient-reported by the 100 mm Visual Analogue Scale (VAS) 5-minutes following the procedure (endometrial biopsy or IUD insertion).",[27,28],"IUD","Endometrial Biopsy",[30,31,32,33],"pain management","iud insertion","endometrial biopsy","gynecology","NOT_YET_RECRUITING","2026-08-11",{"date":37,"type":38},"2026-08-17","ACTUAL",{"date":40,"type":21},"2026-07-30",{"date":42,"type":21},"2027-12-31",{"name":44,"class":45},"Mount Sinai Hospital, Canada","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100632423","phase-4-pipelle-vs-the-curved-aspirator-device-100632423","NCT07513493","Pipelle vs the Curved Aspirator Device","The Conventional Pipelle vs the Curved Aspirator Device: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients \\\u003C18- 45 years with risk factors for endometrial cancer requiring endometrial biopsy.\n2. Patients ≥ 45 -95 years with abnormal uterine bleeding.\n3. Postmenopausal patients with bleeding or suspected endometrial pathology\n\nExclusion Criteria:\n\n1. Any patient who does not meet the inclusion criteria.\n2. Patients with contraindications to endometrial biopsy, including:\n\n   * Pregnancy\n   * Acute pelvic inflammatory disease\n   * Acute cervical infection\n   * Acute vaginal infection\n   * Cervical cancer\n   * Lack of patient consent","95 Years",{"count":56,"type":21},124,[58],"PHASE4","The primary aim of this study is to rigorously compare the efficacy of two commonly used endometrial sampling devices, the Pipelle and the Miltex, these devices are standard of care at Maimonides. This primary objective is critical, as the ability to accurately reach the uterine cavity is fundamental to obtaining adequate samples for histopathological evaluation, which is crucial for diagnosing endometrial cancer and other uterine pathologies.",[28],[62],"Gynecology","RECRUITING","2026-03-30",{"date":66,"type":38},"2026-04-07",{"date":68,"type":38},"2026-01-02",{"date":70,"type":21},"2028-03-31",{"name":72,"class":45},"Maimonides Medical Center",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":46},"100596523","methoxyflurane-for-iud-insertion-and-endometrial-biopsy-100596523","NCT07046572","Methoxyflurane for IUD Insertion and Endometrial Biopsy","A Double-blind Placebo-controlled Randomized Controlled Trial (RCT) of 3ml Methoxyflurane for Intrauterine Device (IUD) Insertion and Endometrial Biopsy","Inclusion Criteria\n\n* Any participant ≥18 years and ≤ 65 years presenting for an IUD insertion or endometrial biopsy\n* For IUD insertion, only nulliparous patients\n* English speaking participants only\n* Availability of a ride home from the appointment\n\nExclusion Criteria\n\n* Use of pain medication that is not an NSAID or acetaminophen (e.g. opioids, benzodiazepines) within past 24 hours\n* Misoprostol administration within 24 hours\n* Breastfeeding\n* Any diagnosed chronic pain syndromes (e.g. fibromyalgia, vaginismus)\n* Allergy to methoxyflurane\n* Renal or liver disease\n* Known or genetically susceptible to malignant hyperthermia or a history of severe adverse reactions in either patient or relatives\n* Baseline vital signs of systolic blood pressure \\\u003C100, diastolic blood pressure \\\u003C60 and\u002For pulse \\\u003C60.\n* Previous unsuccessful office attempt of IUD insertion or endometrial biopsy by the same practitioner (note of clarification: previous unsuccessful IUD insertion or biopsy attempt by a different practitioner will still be eligible)\n* Clinically evident respiratory impairment","65 Years",{"count":20,"type":21},[24],"The aim of this study is to determine if 3ml of inhaled Methoxyflurane, in the form of a Penthrox inhaler, reduces pain during IUD insertion and\u002For endometrial biopsy. The proposed study is a double-blind, placebo-controlled RCT.\n\nEach participant will be randomly assigned to one of two arms:\n\n1. Intervention (3ml of Methoxyflurane via a Penthrox inhaler)\n2. Placebo (3ml of normal saline via an identical placebo Penthrox inhaler)\n\nThe primary outcome is global pain score, which will be patient-reported by the 100 mm Visual Analogue Scale (VAS) 5-minutes following the procedure (endometrial biopsy or IUD insertion).",[28,85],"Intrauterine Devices",[87],"methoxyflurane","2025-07-28",{"date":90,"type":38},"2025-07-30",{"date":92,"type":38},"2025-07-24",{"date":94,"type":21},"2026-03-01",{"name":44,"class":45}]